Rigid amphipathic fusion inhibitors, small molecule antiviral compounds against enveloped viruses
- 7 September 2010
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 107 (40), 17339-17344
- https://doi.org/10.1073/pnas.1010026107
Abstract
Antiviral drugs targeting viral proteins often result in prompt selection for resistance. Moreover, the number of viral targets is limited. Novel antiviral targets are therefore needed. The unique characteristics of fusion between virion envelopes and cell membranes may provide such targets. Like all fusing bilayers, viral envelopes locally adopt hourglass-shaped stalks during the initial stages of fusion, a process that requires local negative membrane curvature. Unlike cellular vesicles, however, viral envelopes do not redistribute lipids between leaflets, can only use the energy released by virion proteins, and fuse to the extracellular leaflets of cell membranes. Enrichment in phospholipids with hydrophilic heads larger than their hydrophobic tails in the convex outer leaflet of vesicles favors positive curvature, therefore increasing the activation energy barrier for fusion. Such phospholipids can increase the activation barrier beyond the energy provided by virion proteins, thereby inhibiting viral fusion. However, phospholipids are not pharmacologically useful. We show here that a family of synthetic rigid amphiphiles of shape similar to such phospholipids, RAFIs (rigid amphipathic fusion inhibitors), inhibit the infectivity of several otherwise unrelated enveloped viruses, including hepatitis C and HSV-1 and -2 (lowest apparent IC50 48 nM), with no cytotoxic or cytostatic effects (selectivity index > 3,000) by inhibiting the increased negative curvature required for the initial stages of fusion.This publication has 53 references indexed in Scilit:
- A broad-spectrum antiviral targeting entry of enveloped virusesProceedings of the National Academy of Sciences of the United States of America, 2010
- Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseasesNature Medicine, 2008
- Retroviruses Human Immunodeficiency Virus and Murine Leukemia Virus Are Enriched in PhosphoinositidesJournal of Virology, 2008
- Drosophila RNAi screen identifies host genes important for influenza virus replicationNature, 2008
- Alteration of viral lipid composition by expression of the phospholipid floppase ABCB4 reduces HIV vector infectivityRetrovirology, 2008
- Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virusProceedings of the National Academy of Sciences of the United States of America, 2007
- Imaging Poliovirus Entry in Live CellsPLoS Biology, 2007
- Missing-in-metastasis and IRSp53 deform PI(4,5)P2-rich membranes by an inverse BAR domain–like mechanismThe Journal of cell biology, 2007
- Isolation and Characterization of Human Immunodeficiency Virus Type 1 Resistant to the Small-Molecule CCR5 Antagonist TAK-652Antimicrobial Agents and Chemotherapy, 2007
- Observation of a Membrane Fusion Intermediate StructureScience, 2002